Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer

Jeannot, Emmanuelle; Latouche, Aurélien; Bonneau, Claire; Calméjane, Marie-Ange; Beaufort, Corine M.; Ruigrok-Ritstier, Kirsten; Bataillon, Guillaume; Chérif, Linda Larbi; Dupain, Célia; Lecerf, Charlotte; Popović, Marina; Rochefordière, Anne de la; Lécuru, Fabrice; Fourchotte, Virginie; Jordanova, Ekaterina S.; Leyen, Heiko von der; Tran-Perennou, Carine; Legrier, Marie-Emmanuelle; Dureau, Sylvain; Raizonville, Laurence; Roufai, Diana Bello; Tourneau, Christophe Le; Bièche, Ivan; Rouzier, Roman; Berns, Els M.J.J.; Kamal, Maud; Scholl, Suzy

doi:10.1158/1078-0432.ccr-21-0625

Cited by 52 publications

(61 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Screening with Pap and/or HPV tests remains the best strategy for cervical cancer screening. Although the value of HPV ctDNA in diagnosing cervical premalignant lesions is limited, we believe that this biomarker might nonetheless have the potential to be applied in disease monitoring following the diagnosis of cancer, as shown elsewhere ( 32 , 35 , 36 ). However, the retrospective design of our study did not include the collection of samples at different time points and, therefore, does not allow the evaluation of this biomarker in disease monitoring.…”

Section: Discussionmentioning

confidence: 67%

Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping Assay

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 67%

Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping Assay

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Additionally, ddPCR platforms are likely to have an increasing role in service laboratories to support precision testing in solid and liquid biopsies including for the measurement of circulating HPV and tumour DNA. [52][53][54] There are limitations to the study--although the sample set was well annotated it was still relatively small. A larger study would have conferred greater power to investigate the impact of viral load, particularly in view of the various adjustments.…”

Section: Viral Load and Impact On Clinical Outcomesmentioning

confidence: 99%

HPV status and HPV16 viral load in anal cancer and its association with clinical outcome

et al. 2022

View full text Add to dashboard Cite

Background:The incidence of anal cancer is increasing globally. Evidence-based improvement in early detection and management of this morbid cancer is thus required. In other cancers associated with Human Papillomavirus (HPV), viral status and dynamics, including viral load (VL) has been shown to influence clinical outcome. Our aim was to determine the influence of HPV status and HPV16 VL on the clinical outcomes of anal cancer patients.Methods: A total of 185 anal cancer lesions were genotyped for HPV. Of the HPV16 positive component, VL was determined using a digital droplet PCR assay.The association of qualitative HPV status and VL (low (<12.3), medium (12.3-57) and high (>57 copies/cell)) on overall survival and hazard of death was assessed.Results: Of the 185 cases, 164 (88.6%) samples were HPV positive. HPV16 was detected in 154/185 samples (83.2%). HPV positive status was associated with improved overall survival in the univariate analysis [hazard ratio (HR) of 0.44, 0.23-0.82, p = 0.01]. When adjusted by age, sex, stage and response to treatment, the association of positive HPV status with improved survival remained (HR 0.24 [0.11-0.55] p < 0.001). High VL was associated with improved overall survival in the univariate analysis with a HR of 0.28 (0.11-0.71, p = 0.007). When adjusted only by age and sex, high VL was associated with better overall survival (HR 0.27, 0.11-0.68 p = 0.006).Conclusions: HPV status appears to be independently associated with improved outcomes in anal cancer patients. Moreover, HPV viral load quantification may be informative for further risk stratification and warrants further investigation.

show abstract

“…In the field of cervical cancer, a trial conducted by Jeannot et al showed that the complete clearance of HPV ctDNA observed by the end of treatment of chemoradiation was significantly associated with a longer DFS and could be used as a reliable marker to predict the risk of relapse [ 41 ]. Unfortunately, in this trial we did not study the HPV ctDNA; further studies will be needed to assess the impact of HPV ctDNA in early-stage cervical cancer.…”

Section: Discussionmentioning

confidence: 99%

Lymph Node Involvement in Early-Stage Cervical Cancer: Is Lymphangiogenesis a Risk Factor? Results from the MICROCOL Study

Tantari

Bogliolo²,

Morotti

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Background: In patients with cervical cancer, the presence of tumoral lymph-vascular space invasion (LVSI) is the main risk factor for pelvic lymph node metastasis (PLNM). The objective of this study was to evaluate the presence of several markers of lymphangiogenesis in early-stage cervical cancer and their correlation with PLNM and tumoral recurrence. Materials and Methods: Seventy-five patients with early-stage cervical carcinoma underwent sentinel lymph node (SLN) sampling in association with complete pelvic lymph node dissection. Primary tumors were stained with the following markers: Ki67, D2-40, CD31 and VEGF-C. A 3-year follow-up was performed to evaluate the disease-free survival. Results: Overall, 14 patients (18.6%) had PLNM. Positive LVSI was seen in 29 patients (38.6%). There was a significant correlation between LVSI evidenced by H/E staining and PLNM (p < 0.001). There was no correlation between high Ki67, CD31, D2-40, and VEGF-C staining with PLNM or tumor recurrence. Conclusions: Our data support that lymphatic spread does not require the proliferation of new lymphatic endothelial cells in early-stage cervical cancer. These results emphasize the importance of pre-existing peritumoral lymphatic vessels in the metastatic process in early cervical cancer. None of the markers of lymphangiogenesis and proliferation assessed in this study were predictive of PLNM or recurrence.

show abstract

Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer

Abstract: Financial support: European Union's Seventh Program for research, technological development and demonstration (agreement N°304810), the Fondation ARC pour la recherche contre le cancer.

Cited by 52 publications

References 42 publications

Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping Assay

Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping Assay

HPV status and HPV16 viral load in anal cancer and its association with clinical outcome

Lymph Node Involvement in Early-Stage Cervical Cancer: Is Lymphangiogenesis a Risk Factor? Results from the MICROCOL Study

Contact Info

Product

Resources

About